Study to Evaluate Safety and Immunogenicity of Butantan Seasonal Influenza Vaccine - FLU-02-IB

Inclusion Criteria: * Healthy adults, male or female aged 18 to 59 * Elderly aged 60 years completed and above * To be available to participate in the study throughout its duration (approximately 21 days) * To have medical indication to be vaccinated against influenza * To demonstrate intention to participate in the study, as documented by signature in the study´s informed consent form. Exclusion Criteria: * Evidence of active neurological, cardiac, pulmonary, hepatic or renal disease as clinical history and/or physical examination (except hypertension under control among the elderly) * Compromised immune system diseases including: HIV, diabetes mellitus, cancer (except basal cell carcinoma) and autoimmune diseases * Behavioral, cognitive or psychiatric disease that in the opinion of the principal investigator or his representative physician, affects the participant ability to understand and cooperate with all study protocol requirements * Abusive usage of alcohol or drugs in the past 12 months that has caused medical, professional or family problems, indicated by clinical history * Known systemic hypersensitivity to eggs or to any component of the vaccine * History of severe adverse reaction after previous administration of an Influenza vaccine within 6 weeks following vaccination